IGM Biosciences Inc

Latest Results (06.11.2025):

IGM Biosciences Inc reported its Q2 2025 financial results with notable earnings and revenue surprises. The company posted adjusted earnings of $1.58 per share, significantly outperforming estimates that predicted a loss, and delivered revenues of $143.62 million, marking a dramatic improvement compared to the prior year.

Earnings Beat and Surprise

The company recorded an adjusted EPS of $1.58 for Q2 2025, outperforming estimates of a loss and representing an impressive earnings surprise of +626.67% compared to prior forecasts. This remarkable turnaround stands in contrast to the previous quarter’s results and also shows improvement over last year's loss of $0.79 per share.

Revenue Surge

IGM Biosciences Inc achieved revenues of $143.62 million for Q2 2025, vastly surpassing expectations by 4,388.22% compared to estimates and dwarfing the year-ago revenue of $1.25 million. This significant revenue growth highlights the company's dramatic expansion within the quarter.

Outlook and Market Context

While the results showcase strong performance in Q2 2025, management’s upcoming commentary and revisions to future earnings estimates will be critical in defining the immediate trajectory of the stock. Despite the impressive quarterly performance, the stock has underperformed on a year-to-date basis, reflecting broader market concerns.